How Should We Determine the Value of CAR T-Cell Therapy
Bibliographic Data
| ID | 15745284 |
|---|---|
| Authors | Sara Silbert (0000-0002-2746-9410, University of Michigan, corresponding author), Gregory A Yanik (0000-0003-3829-4940, University of Michigan), Andrew G Shuman (0000-0002-9305-7860, University of Michigan) |
| Year | 2019 |
| Volume | 21 |
| Issue | 10 |
| Pages | E844-851 |
| Publication date | 2019-10-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | The AMA Journal of Ethic (JOURNAL) |
| Journal identifiers | ISSN: 2376-6980 • E-ISSN: 2376-6980 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/amajethics.2019.844 |
| PMID | 31651383 |
| OpenAlex | W2978959216 |
| Language | EN |
| Citations received | 1 |
| References cited | 1 |
In 2017, the US Food and Drug Administration approved the first chimeric antigen receptor (CAR) T-cell therapies for patients with relapsed or refractory B-cell leukemia and selected B-cell lymphomas. This novel form of cellular immunotherapy creates a "living drug" that effectively reprograms a patient's T cells to target specific antigens on the surface of a tumor. The therapy has high response rates in patients with refractory disease, although a single infusion of CAR T cells costs hundreds of thousands of dollars. A value analysis is required to determine whether and how to offer patients these expensive, customized drugs
Antigen · Biology · Cell · Cell therapy · Chimeric antigen receptor · Disease · Drug · Food and drug administration · Immune system · Immunotherapy · Leukemia · Lymphoma · Refractory (planetary science · Biomedical Ethics and Regulation · CAR-T cell therapy research · Medicine · Cancer Research · Immunology · Internal Medicine · Oncology · Pharmacology
| Citations per year | 0.25 |
|---|---|
| Citation span | 2022 - 2022 (1) |
| Highly cited | No |